MF Researcher Database

Researcher Database

Advance

Fujita Ken-Ichi

■FacultyCancer Genome and Pharmacotherapy
■PositionProfessor
Last Updated :2025/04/01

Researcher

基本情報

Profile and Settings

  • 氏名

    Fujita Ken-Ichi

Affiliation

  • Cancer Genome and Pharmacotherapy, Professor

Location

  • Hatanodai Campus

Degree

  • Doctor of Pharmaceutical Science, Hokkaido University, Sep. 2001

Achievements

Published Papers

  • Development of radioiodine-labeled mequitazine for evaluation of hepatic CYP2D activity., Asuka Mizutani, Masato Kobayashi, Kodai Nishi, Ken-ichi Fujita, Kotaro Takahashi, Yuka Muranaka, Kakeru Satou, Masanori Kitamura, Chie Suzuki, Ryuichi Nishii, Naoto Shikano, Yasuhiro Magata, Yasushi Ishida, Munetaka Kunishima, Kazuki Fukuchi, Keiichi Kawai, Front. Pharmacol., Jun. 2024, Peer-reviewed
  • Endoplasmic reticulum transporter OAT2 regulates drug metabolism and interaction, Arakawa H, Ishida N, Nakatsuji T, Matsumoto N, Imamura R, Shengyu D, Araya K, Horike S, Tanaka-Yachi R, Kasahara M, Yoshioka T, Sumida Y, Ohmiya H, Daikoku T, Wakayama T, Nakamura K, Fujita K, Kato Y, Biochem. Pharmacol., May 2024, Peer-reviewed
  • Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reactions and survival of regorafenib in Japanese patients with colorectal cancer, Koutaro Ono; Remi Murase; Natsumi Matsumoto; Yutaro Kubota; Hiroo Ishida; Ken-ichi Fujita, Cancer Chemotherapy and Pharmacology, 2024, Peer-reviewed
  • Association Between ABCC2 -24C>T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients With Pancreatic Cancer., Nakayama Hana;Ishida Hiroo;Iidaka Masanori;Kato Shoko;Nakatani Kei;Nakayama Akihiro;Noguchi Toshihiro;Nishihara Shigetoshi;Oikawa Shu;Usami Tomono;Mitsui Yuta;Ishii Y U;Toshima Hirokazu;Kobayashi Kouji;Murase Remi;Matsumoto Natsumi;Suzuki Kosuke;Shimada Ken;Yoshida Hitoshi;Fujita Ken-Ichi, Anticancer research, 44(11), 2024, Peer-reviewed
  • Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer, Ken-ichi Fujita, Natsumi Matsumoto, Remi Murase, Kosuke Takeshima, Hiroo Ishida, Yutaro Kubota, Clinical and Translational Sicnese, 16(10):1741 - 1747, Jun. 2023, Peer-reviewed, DOI:10.1111/cts.13589
  • Adeno-associated virus-mediated knockdown demonstrates the major role of hepatic Bcrp in the overall disposition of the active metabolite of the tyrosine kinase inhibitor regorafenib in mice., Aya Hasan Alshammari, Yusuke Masuo, Shotaro Yoshino, Reiya Yamashita, Takahiro, Ishimoto, Ken-ichi Fujita, Yukio Kato, Drug Metabolism and Pharmacokinetics, 49:100483, Nov. 2022, DOI:10.1016/j.dmpk.2022.100483
  • Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study., Nio Yuta;Ishida Hiroo;Matsumoto Natsumi;Kusumoto Sojiro;Kubota Yutaro;Tsunoda Takuya;Sasaki Yasutsuna;Fujita Ken-Ichi, BMC pulmonary medicine, 22(1):454, Nov. 2022, DOI:10.1186/s12890-022-02249-8
  • Application of Personal Health Record in Enhancing the Quality of Life in Patients With Breast Cancer Who Received Adjuvant Hormonal Therapy., Takada Fuka;Okuyama Hiromi;Nakamura Seigo;Fujita Ken-Ichi, European journal of breast health, 18(2):155 - 162, Apr. 2022, DOI:10.4274/ejbh.galenos.2022.2021-12-2
  • Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition., ALSHAMMARI Aya Hasan ;MASUNO Yusuke;FUJITA Ken-ichi;SHIMADA Kazuhiro;IIDA Noriho;WAKAYAMA Tomohiko;KATO Yukio, Biochem Pharmacol, 197:114914, Mar. 2022, Peer-reviewed
  • Characteristics of miRNA-SNPs in healthy Japanese subjects and non-small cell lung cancer, colorectal cancer, and soft tissue sarcoma patients., KATAYAMA Koki;NAKASHIMA Shimon;ISHIDA Hiroo;KUBOTA Yutaro;NAKANO Masataka;FUKAMI Tatsuki;SASAKI Yasutsuna;FUJITA Ken-ichi;NAKAJIMA Miki, Non-coding RNA Res, :e, Jun. 2021, Peer-reviewed
  • Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure., TSUBOYA Ayako;KUBOTA Yutaro;ISHIDA Hiroo;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;SASAKI Yasutsuna;MATSUMOTO Natsumi;KONDO Yusuke;TOMODA Yukana;KUSUHARA Hiroyuki;FUJITA Ken-ichi, Cancer Chemother Pharmacol, :e, Jun. 2021, Peer-reviewed
  • Correlation between the metabolic conversion of a capecitabine metabolite, 5′-deoxy-5-fluorocytidine, and creatinine clearance, INAISHI Takahiro;FUJITA Ken-ichi;MATSUMOTO Natsumi;SHIMOKATA Tomoya;MAEDA Osamu;KIKUMORI Toyone;HATTORI Norifumi;NAKAYAMA Goro;ANDO Yuichi, In Vivo, 34(6):3539 - 3544, Nov. 2020, Peer-reviewed
  • 6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients, MASUO Yusuke;FUJITA Ken-ichi;MISHIRO Kenji;SEBA Natsumi;KOGI Tatsuya;OKUMURA Hidenori;MATSUMOTO Natsumi;KUNISHIMA Munetaka;KATO Yukio, Drug Metab Pharmacokinet, 35(6):555 - 562, Sep. 2020, Peer-reviewed
  • Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients., Kubota Yutaro;Fujita Ken-Ichi;Takahashi Takehiro;Sunakawa Yu;Ishida Hiroo;Hamada Kazuyuki;Ichikawa Wataru;Tsunoda Takuya;Shimada Kazuhiro;Masuo Yusuke;Kato Yukio;Sasaki Yasutsuna, Clinical pharmacology and therapeutics, 108(3):586 - 595, Sep. 2020, Peer-reviewed
  • 製鉄所のエンジニアと抗がん薬の臨床薬理研究　(第10回 前キャリアが今に生きること), 藤田　健一, ファルマシア, 56(8):774 - 775, Aug. 2020
  • Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients, MATSUMOTO Natsumi;KUBOTA Yutaro;ISHIDA Hiroo;SEKIDO Masae;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;IKUSUE Toshikazu;KOBAYASHI Kouji;HISAMATSU Atsushi;TOSHIMA Hirokazu;SHIMADA Ken;FUJITA Ken-ichi, Cancer Chemother Pharmacol, 85(6):1119 - 1128, Jun. 2020, Peer-reviewed
  • High expression of FOXM1 critical for sustaining cell proliferation in mitochondrial DNA-less liver cancer cells., Higurashi Masato;Maruyama Tsuyoshi;Nogami Yusuke;Ishikawa Fumihiro;Yoshida Yukiko;Mori Kazunori;Fujita Ken-Ichi;Shibanuma Motoko, Experimental cell research, 389(1):111889, Apr. 2020, Peer-reviewed
  • Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel., Mori Daiki;Ishida Hiroo;Mizuno Tadahaya;Kusumoto Sojiro;Kondo Yusuke;Izumi Saki;Nakata Genki;Nozaki Yoshitane;Maeda Kazuya;Sasaki Yasutsuna;Fujita Ken-Ichi;Kusuhara Hiroyuki, Drug metabolism and disposition: the biological fate of chemicals, 48(5):dmd.119.089474, Feb. 2020, Peer-reviewed
  • High-throughput method to analyze tegafur and 5-fluorouracil in human tears and plasma using hydrophilic interaction liquid chromatography/tandem mass spectrometry, SHIOKAWA Ritsuko;LEE Xiao-Pen;YAMADA Miho;FUJISHIRO Masaya;SAKAMAKI Hiroshi;HASEGAWA Chika;ISHIDA Hiroo;IKEDA Kenichiro;FUJITA Ken-ichi;IWABUCHI Shigehiro;ONDA Hidetoshi;KUMAZAWA Takeshi;SASAKI Yasutsuna;SATO Keizo;MATSUYAMA Taka-aki, Rapid Commun Mass Spectrom, 33(24):1906 - 1914, Dec. 2019, Peer-reviewed
  • Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice., Al-Shammari Aya Hasan;Masuo Yusuke;Fujita Ken-Ichi;Yoshikawa Yuka;Nakamichi Noritaka;Kubota Yutaro;Sasaki Yasutsuna;Kato Yukio, Journal of pharmaceutical sciences, 108(6):2173 - 2179, Jun. 2019, Peer-reviewed
  • Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil., Sekido Masae;Fujita Ken-Ichi;Kubota Yutaro;Ishida Hiroo;Takahashi Takehiro;Ohkuma Ryotaro;Tsunoda Takuya;Ishikawa Fumihiro;Shibanuma Motoko;Sasaki Yasutsuna, Cancer chemotherapy and pharmacology, 83(6):1127 - 1135, Jun. 2019, Peer-reviewed
  • Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38., Iwase Mariko;Fujita Ken-Ichi;Nishimura Yuki;Seba Natsumi;Masuo Yusuke;Ishida Hiroo;Kato Yukio;Kiuchi Yuji, Cancer chemotherapy and pharmacology, 83(5):993 - 998, May 2019, Peer-reviewed
  • Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure, FUJITA Ken-ichi;MATSUMOTO Natsumi;ISHIDA Hiroo;KUBOTA Yutaro;IWAI Shinichi;SHIBANUMA Motoko;KATO Yukio, Curr Drug Metab, 20(5):361 - 376, Mar. 2019, Peer-reviewed
  • Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer., TSUBOYA Ayako;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;TAKI (TAKEMOTO) Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, Int J Clin Oncol, 24(2):222 - 230, Feb. 2019, Peer-reviewed
  • KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR., NAKATANI Kaori;YAMAOKA Toshimitsu;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;KUSUMOTO Sojiro;TAKI (TAKEMOTO) Iori;KAMEI Daisuke;IWAI Shinichi;TSURUTANI Junji;OHMORI Tohru, Mol Cancer Ther, 18(1):112 - 126, Jan. 2019, Peer-reviewed
  • 123I-iomazenil whole-body imaging to detect hepatic carboxylesterase drug-metabolizing enzyme activity, MIZUTANI Asuka;KOBAYASHI Masato;FUJITA Ken-ichi;TAKAHASHI Kotaro;HOKAMA Tsuzumi;TAKASU Hiroaki;NISHI Kodai;NISHII Ryuichi;SHIKANO Naoto;FUKUCHI Kazuki;KAWAI Keiichi, Nucl Med Commun, 39(9):825 - 833, Sep. 2018, Peer-reviewed
  • Development of evaluation method for the potential of OATP1B-mediated DDI using endogenous conpounds, 楠原　洋之;森　大輝;藤田　健一;佐々木　康綱;杉山　雄一, 臨床薬理の進歩, (39):57 - 65, Jun. 2018
  • Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib, ELLAWATTY Waleed Elsayed Ahmed;MASUO Yusuke;FUJITA Ken-ichi;YAMAZAKI Erina;ISHIDA Hiroo;ARAKAWA Hiroshi;NAKAMICHI Noritaka;ABDELWAHED Ramadan;SASAKI Yasutsuna;KATO Yukio, Drug Metab Dispos, 46(1):33 - 40, Jan. 2018, Peer-reviewed
  • 薬効別にみた薬物動態と臨床でのポイント　細胞障害性抗がん薬, 藤田　健一, 薬事, 59(14):3004 - 3011, Oct. 2017
  • Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites., Fujita Ken-Ichi;Masuo Yusuke;Yamazaki Erina;Shibutani Toshiki;Kubota Yutaro;Nakamichi Noritaka;Sasaki Yasutsuna;Kato Yukio, Journal of pharmaceutical sciences, 106(9):2632 - 2641, Sep. 2017, Peer-reviewed
  • Comprehensive microRNA-SNPs analysis in Japanese for optimized cancer pharmacotherapy, 中島　美紀;藤田　健一;佐々木　康綱, 臨床薬理の進歩, (38):121 - 128, Jun. 2017
  • Toxicities of receptor tyrosine kinase inhibitors in cancer pharmacotherapy: management with clinical pharmacology, FUJITA Ken-ichi;ISHIDA Hiroo;KUBOTA Yutaro;SASAKI Yasutsuna, Curr Drug Metab, 18(3):186 - 198, Mar. 2017, Peer-reviewed
  • Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan., TAKATA Kosuke;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;ICHIKAWA Wataru;SHIMADA Ken;SEKIKAWA Takashi;TAKI-TAKEMOTO Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, J Pharm Health Care Sci, 2(30):1 - 9, Nov. 2016, Peer-reviewed
  • Investigation of bioequivalence between brand-name and generic irinotecan products., SAITO Ken-ichi;INOUE Yutaka;IKEGAMI Yoji;NANBO Izumi;ONOZUKA Mari;SANO Kazumi;YOSHIDA Hisahiro;SAKAMOTO Toshihiro;TATEBAYASHI Emi;FUJITA Ken-ichi;SASAKI Yasutsuna;KITAZAWA Takaki, Anticancer Res, 39(11):5957 - 5963, Nov. 2016, Peer-reviewed
  • A comparison of four methods for detecting KRAS mutations in formalin-fixed specimens from metastatic colorectal cancer patients, MATSUNAGA Mototsugu;KANETA Toshikado;MIWA Keisuke;ICHIKAWA Wataru;FUJITA Ken-ichi;NAGASHIMA Fumio;FURUSE Junji;KAGE Masayoshi;AKAGI Yoshito;SASAKI Yasutsuna, Oncol Lett, 12(1):150 - 156, Jul. 2016, Peer-reviewed
  • Over 80歳のがん診療とその臨床的課題 併存疾患を有する高齢がん患者への対応　polypharmacy, 藤田　健一, Cancer Board Square, 2(2):280 - 284, Jul. 2016
  • HILIC-MS/MS法によるヒト涙液中tegafurおよび5-fluorouracilの高感度分析法, 小渕　律子;李　暁鵬;石田　博雄;熊澤　武志;池田　賢一郎;藤城　雅也;藤田　健一;佐藤　淳一;澤口　聡子;高橋　春男;佐藤　啓造, 昭和学士会雑誌, 76(3):299 - 307, Jun. 2016, Peer-reviewed
  • Bioequivalence studies of a generic formulation (SW651K) to the brand drug S-1 in tumor-bearing rat models, OKABE Tomoyuki;OGURA Takeharu;YOSHIMURA Takashi;TANAKA Yoshiyuki;TOYODA Hiromu;FUJITA Ken-ichi;SASAKI Yasutsuna, J Bioequiv Availab, 8(3):112 - 117, May 2016, Peer-reviewed
  • Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer, HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OKUDA Kentaro;OHMORI Tohru;SASAKI Yasutsuna, Lung Cancer, 93:69 - 76, Mar. 2016, Peer-reviewed
  • Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction, SHIBATA Takashi;EBATA Tomoki;FUJITA Ken-ichi;SHIMOKATA Tomoya;MAEDA Osamu;MITSUMA Ayako;SASAKI Yasutsuna;NAGINO Masato;ANDO Yuichi, Cancer Sci, 107(2):168 - 172, Feb. 2016, Peer-reviewed
  • Atypical pharmacokinetics and toxicity of irinotecan hydrochloride in cancer patients with severe renal failure who were undergoing dialysis, 藤田　健一, 日本透析医会雑誌, 30(3):538 - 542, Dec. 2015, Peer-reviewed
  • Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer, FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;SASAKI Yasutsuna, World J Gastroenterol, 21(43):12234 - 12248, Nov. 2015, Peer-reviewed
  • A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer, FUJITA Ken-ichi;YOSHINO Etsuko;KAWARA Kaori;MAEDA Kazuya;KUSUHARA Hiroyuki;SUGIYAMA Yuichi;YOKOYAMA Taro;KANETA Toshikado;ISHIDA Hiroo;SASAKI Yasutsuna, Cancer Chemother Pharmacol, 76(4):793 - 801, Oct. 2015, Peer-reviewed, DOI:10.1007/s00280-015-2844-2
  • Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology, AMEMIYA Takahiro;HONMA Masashi;KARIYA Yoshiaki;GHOSH Samik;KITANO Hiroaki;KURACHI Yoshihisa;FUJITA Ken-ichi;SASAKI Yasutsuna;HOMMA Yukio ;ABERNETHY Darrel;KUME Haruki;SUZUKI Hiroshi, NPJ Syst Biol Appl, 1:e15005, Sep. 2015, Peer-reviewed, DOI:10.1038/npjsba.2015.5
  • An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients., ICHIKAWA Wataru;UEHARA Keisuke;MINAMIMURA Keisuke;TANAKA Chihiro;TAKII Yasumasa;MIYAUCHI Hideaki;SADAHIRO Sotaro;FUJITA Ken-ichi;MORIWAKI Toshikazu;NAKAMURA Masato;TAKAHASHI Takehiro;TSUJI Akihito;SHINOZAKI Katsunori;MORITA Satoshi;ANDO Yuichi;OKUTANI Yukihiro;SUGIHARA Masahiro;SUGIYAMA Toru;OHASHI Yasuo;SAKATA Yuh, Br J Cancer, 112(10):1709 - 1716, May 2015, Peer-reviewed
  • In Vivo Radioactive Metabolite Analysis for Individualized Medicine: A Basic Study of a New Method of CYP Activity Assay using 123I-IMP., NISHI Kodai;MIZUTANI Asuka;SHIKANO Naoto;FUJITA Ken-ichi;KOBAYASHI Masato;ONO Masahiro;NISHII Ryuichi;SASAKI Yasutsuna;KINUYA Seigo;KAWAI Keiichi, Nucl Med Biol, 42(2):171 - 176, Feb. 2015, Peer-reviewed
  • High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer., FUJITA Ken-ichi;HIROSE Takashi;KUSUMOTO Sojiro;SUGIYAMA Tomohide;SHIRAI Takao;NAKASHIMA Masanao;AKIYAMA Yuko;SASAKI Yasutsuna, Lung Cancer, 86(1):113 - 114, Oct. 2014, Peer-reviewed
  • No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion., KANETA Toshikado;FUJITA Ken-ichi;AKIYAMA Yuko;KAWARA Kaori;SUNAKAWA Yu;KAWACHI Asuka;SHIMADA Ken;SASAKI Yasutsuna, Cancer Chemother Pharmacol, 74(3):539 - 547, Sep. 2014, Peer-reviewed
  • Atypical pharmacokinetics of anticancer drug mainly eliminated via the liver in cancer patients with severe renal failure., 藤田　健一, ファルマシア, 50(4):300 - 304, Apr. 2014, Peer-reviewed
  • Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans, FUJITA Ken-ichi;SUGIURA Tomoko;OKUMURA Hidenori;UMEDA Saki;NAKAMICHI Noritaka;WATANABE Yusuke;SUZUKI Hiromichi;SUNAKAWA Yu;SHIMADA Ken;KAWARA Kaori;SASAKI Yasutsuna;KATO Yukio, Pharm Res, 31(1):204 - 215, Jan. 2014, Peer-reviewed
  • Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world', FUJITA Ken-ichi;SASAKI Yasutsuna, Drug Metab Pharmacokinet, 29(1):20 - 28, Jan. 2014, Peer-reviewed
  • 腎機能障害患者における抗がん薬の薬物動態、抗がん薬による腎機能障害, 藤田　健一, 月刊薬事, 55(13):2341 - 2345, Dec. 2013
  • Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer., SASAKI Tetsuya;FUJITA Ken-ichi;SUNAKAWA Yu;ISHIDA Hiroo;YAMASHITA Keishi;MIWA Keisuke;SAJI Shigehira;KATO Yasuhisa;SASAKI Yasutsuna, Int J Clin Oncol, 18(4):735 - 742, Aug. 2013, Peer-reviewed

Presentations

  • 肝臓におけるヒト膜輸送体BCRPの機能評価系構築：アデノ随伴ウイルスを用いたアプローチ．, 吉野将太郎、増尾友佑、山下怜矢、藤田健一、加藤将夫, 第145回日本薬学年会, 28 Mar. 2025
  • Effect of base-line plasma albumin and unbound plasma level of lenvatinib in patients with hepatocellular carcinoma, 鈴木康介、音山裕美、中島陽子、杉浦育也、冨士貴弘、野村英里佳、市川雪、下間祐、打越学、坂木理、水戸守智香、増尾友佑、早野桃花、松本奈都美、村瀬礼美、加藤将夫、吉田仁、藤田健一, 2025 the Japanese Society of Medical Oncology Annual Meeting, 07 Mar. 2025, Japanese Society of Medical Oncology, 神戸コンベンションセンター
  • A polymorphism in ABCC3 is associated with capecitabine-induced hand-foot syndrome and capecitabine pharmacokinetics, Kengo Omata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida3 Ken Shimada, and Ken-ichi Fujita, 2025 the Japanese Society of Medical Oncology Annual Meeting, 06 Mar. 2025
  • Association between ABCC2 -24C>T and nab-paclitaxel-induced peripheral neuropathy in Japanese patients with pancreatic cancer, Hana Nakayama,Hiroo Ishida, Masanori Iidaka, Shoko Kato, Kei Nakatani, Akihiro Nakayama, Toshihiro Noguchi, Shigetoshi Nishihara, Shu Oikawa, Tomono Usami, Yuta Mitsui, Yu Ishii, Hirokazu Toshima, Kouji Kobayashi, Remi Murase, Natsumi Matsumoto, Kosuke Suzuki, Ken Shimada, Hitoshi Yoshida, Ken-ichi Fujita, 2025 the Japanese Society Medical Oncology annual Meeting, 06 Mar. 2025, 日本臨床腫瘍学会, 神戸
  • Involvement of efflux transporters ABCG2 and ABCB1 in overall disposition of multikinase inhibitor pazopanib, Ruth Shekina Lumumba, Yusuke Masuo, Shotaro Yoshino, Ken-ichi Fujita, Yukio Kato, 39th Japanese Society for the Study of Xenobiotics annual meeting, 18 Sep. 2024
  • ABCC4 genetic polymorphism may indirectly regulate disposition of capecitabine metabolite in colorectal cancer patients., Yusuke Masuo, Natsumi Matsumoto, Ayano Oishi, Yui Ikeda, Ken-ichi Fujita, Yukio Kato, 39th Japanese Society for the Study of Xenobiotics annual meeting, 18 Sep. 2024
  • Construction of functional evaluation system for human BCRP-mediated biliary excretion using adeno-associated virus., Shotaro Yoshino, Yusuke Masuo, Reiya Yamashita, Ken-ichi Fujita, Yukio Kato, 39th Japanese Society for the Study of Xenobiotics annual meeting, 16 Sep. 2024
  • Reduced systemic exposure to a capecitabine metabolite 5'-DFUR in ABCC4 polymorphism may be associated with increases in cAMP level and subsequent upregulation of thymidine phosphorylase, Natsumi Matsumoto, Ayano Oishi, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Yusuke Masuo, Yukio Kato, Ken-ichi Fujita, ASCPT 2024 Annual Meeting, 28 Mar. 2024, American Society for Clinical Pharmacology & Therapeutics, Colorado Springs, United States
  • Reduced systemic exposure to a capecitabine metabolite 5'-DFUR in ABCC4 polymorphism may be associated with increases in cAMP level and subsequent upregulation of thymidine phosphorylase, Natsumi Matsumoto, Ayano Oishi, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Yusuke Masuo, Yukio Kato, Ken-ichi Fujita, ASCPT 2024 Annual Meeting, 28 Mar. 2024, American Society for Clinical Pharmacology & Therapeutics, Colorado Springs, United States
  • Effect of VEGFA and CCL4L2 variants on hand-foot skin reaction and survival of regorafenib in Japanese patients with CRC, Koutaro Ono; Remi Murase; Natsumi Matsumoto; Yutaro Kubota; Hiroo Ishida; Ken-ichi Fujita, 2024 the Japanese Society Medical Oncology Annual Meeting, 22 Feb. 2024, Hirogi Iwata, Nagoya Congress Center
  • Involvement of BCRP and other efflux transporters in pharmacokinetics of pazopanib in mice., Ruth Shekina Lumumba, Yusuke Masuo, Shotaro Yoshino, Ken-ichi Fujita, Yukio Kato, 38th Japanese Society for the Study of Xenobiotics annual meeting, 28 Sep. 2023, Shizuoka
  • Regulation of drug-metabolizing enzymes activity by ABCC4 expression in liver., Ikeda Y, Masuo Y, Oishi A, Matsumoto N, Fujita KI, Kato Y, The 38th Annual Meeting of Japanese Society for the Study of Xenobiotics, 28 Sep. 2023
  • Investigation of the role of human hepatic Bcrp by using adeno-associated virus mediated gene delivery., Shotaro Yoshino, Yusuke Masuo, Reiya Yamashita, Ken-ichi Fujita, Yukio Kato, 38th Japanese Society for the Study of Xenobiotics annual meeting, 27 Sep. 2023, Shizuoka
  • Associations of polymorphisms in CCL4L1 with regorafenib-induced hand-foot skin reaction in colorectal cancer patients, Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Takuya Tsunoda, Yasutsuna Sasaki, Ken-ichi Fujita, 2023 the Japanese Society of Medical Oncology Annual Meeting. The 20th Anniversary Meeting, 16 Mar. 2023, Japanese Society of Medical Oncology, Fukuoka International Congress Center/ Marine Messe
  • A polymorphisms in ABCA2 is associated with pharmacokinetics and toxicity of capecitabine in colorectal cancer patients, Yukitaka Shibata, Natsumi Matsumoto, Yutaro Kubota, Takuya Tsunoda, Hiroo Ishida, Ken Shimada, Ken-ichi Fujita, The 20th Japanese Society of Medical Oncology annual meeting, 16 Mar. 2023, Fukuoka
  • レンバチニブ投与患者血漿検体のメタボロミクス解析による薬効バイオマーカー探索, 水戸守智香、 増尾友佑、 荒井潤、 松本奈都美、 鈴木康介、 吉田仁、藤田健一、 加藤将夫, 第43回日本臨床薬理学会学術総会, 30 Nov. 2022
  • Effect of genetic mutation of the endoplasmic reticulum membrane transporter OAT2 on the pharmacokinetics of the anticancer drug capecitabine., Naoki Ishida, Hiroshi Arakawa, Natsumi Matsumoto, Ken-ichi Fujita, Yukio Kato, 37th Japanese Society for the Study of Xenobiotics annual meeting, 08 Nov. 2022
  • Estimation of pharmacokinetic parameter alternation for capecitabine and its metabolites in colorectal cancer patients with ABCC4 genetic polymorphism., Ayano Oishi, Yusuke Masuo, Natsumi Matsumoto, Ken-ichi Fujita, Yukio Kato, 37th Japanese Society for the Study of Xenobiotics annual meeting, 08 Nov. 2022
  • Investigation of the role of hepatic Bcrp by using adeno-associated virus mediated gene knockdown., Shotaro Yoshino, Yusuke Masuo, Reiya Yamashita, Ken-ichi Fujita, Yukio Kato, 37th Japanese Society for the Study of Xenobiotics annual meeting, 08 Nov. 2022
  • Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with colorectal cancer., TAKESHIMA Kousuke;MATSUMOTO Natsumi;KUBOTA Yutaro;ISHIDA Hiroo;TSUNODA Takuya;SASAKI Yasutsuna;FUJITA Ken-ichi, 123rd American Society for Clinical Pharmacology and Therapeutics annual meeting (accepted)., 16 Mar. 2022, Web
  • Regorafenib-induced erythema multiforme is associated with HLA-C*01:02 and HLA-B*46:01 in Japanese cancer patients, 松本　奈都美;竹島　功高;久保田　祐太郎;石田　博雄;角田　卓也;佐々木　康綱;藤田　健一, 第19回日本臨床腫瘍学会学術集会(JSMO2022), 18 Feb. 2022, 京都＋Web開催
  • Pharmacokinetics and toxicity of gefitinib in elderly patients with EGFR mutated non-small cell lung cancer, 石田　博雄;仁尾　祐太;松本　奈都美;楠本　壮二郎;久保田　祐太郎;角田　卓也;佐々木　康綱;藤田　健一, 第19回日本臨床腫瘍学会学術集会(JSMO2022), 17 Feb. 2022, 京都＋Web開催
  • Pharmacokinetics and toxicity of gefitinib in elderly patients with EGFR mutated non-small cell lung cancer, 石田　博雄;仁尾　祐太;松本　奈都美;楠本　壮二郎;久保田　祐太郎;角田　卓也;佐々木　康綱;藤田　健一, 第19回日本臨床腫瘍学会学術集会(JSMO2022), 17 Feb. 2022, 京都＋Web開催
  • Construction of physiologically based pharmacokinetic model of capecitabine and its metabolites in colorectal cancer patients with genetic polymorphism in ABC transporter gene., OISHI Ayano;MATSUMOTO Natsumi;FUJITA Ken-ichi;KATO Yukio, 日本薬物動態学会 第36回年会, 19 Nov. 2021, Web Meeting
  • Involvement of BCRP/ABCG2 in gastrointestinal absorption and biliary excretion of a multi-kinase inhibitor pazopanib, YOSHINO Shotaro;MASUO Yusuke;ISHIDA Hiroo;FUJITA Ken-ichi;KATO Yukio, 日本薬物動態学会 第36回年会, 18 Nov. 2021, Web Meeting
  • 抗悪性腫瘍薬の効果・毒性と遊離形血漿中濃度 (シンポジウム), 藤田　健一, 第28回HAB研究機構学術年会, 04 Jun. 2021, オンライン学会
  • Capecitabineの加水分解反応における小胞体膜輸送体OAT2の役割, 石田　尚輝;荒川　大;松本　奈都美;藤田　健一;加藤　将夫, 日本薬剤学会第36年会, 13 May 2021, オンライン開催
  • SN-38の体内動態とOATP1B1の機能:重篤な腎機能障害のない患者において, 藤田　健一;久保田　祐太郎;石田　博雄;坪谷　綾子;角田　卓也;松本　奈都美;楠原　洋之;佐々木　康綱, 第18回日本臨床腫瘍学会学術集会 (JSMO2021), 18 Feb. 2021, オンデマンド配信
  • 抗悪性腫瘍薬イリノテカンの活性代謝物SN-38の体内動態とOATP1B1輸送活性との関連, 藤田　健一;久保田　祐太郎;石田　博雄;坪谷　綾子;角田　卓也;松本　奈都美;楠原　洋之;佐々木　康綱, 第41回日本臨床薬理学会学術総会, 05 Dec. 2020, 福岡およびWeb会場
  • ABCC4遺伝子多型のカペシタビンと代謝物の体内動態への影響, 松本　奈都美;久保田　祐太郎;角田　卓也;石田　博雄;嶋田　顕;増尾　友佑;加藤　将夫;藤田　健一, 第41回日本臨床薬理学会学術総会, 03 Dec. 2020, 福岡およびWeb会場
  • 健常成人におけるフルルビプロフェンの蛋白結合におよぼす遊離脂肪酸の影響, 緒方　賢次;内田　直樹;髙村　徳人;藤田　健一;瀬戸口　奈央;徳永　仁, 第41回日本臨床薬理学会学術総会, 03 Dec. 2020, 福岡およびWeb会場
  • Association between pharmacokinetics and dermal toxicology of tyrosine kinase inhibitors in a mouse model, アルシャッマリ　アヤ;増尾　友佑;島⽥　和弘;藤田　健一;若⼭　友彦;加藤　将夫, 日本薬物動態学会第35年会, 01 Dec. 2020, Web開催
  • No effects of variants in carboxylesterase 1 gene on pharmacokinetics of capecitabine and its metabolites, 松本　奈都美;久保田　祐太郎;石田　博雄;関戸　匡恵;柴沼　質子;嶋田　顕;藤田　健一, 日本薬学会第140年会, 26 Mar. 2020, Web公開
  • Effect of a tyrosine kinase inhibitor regorafenib on the expression of xenobiotic transporters in the liver: Possible association with accumulation of its active metabolite., HASAN Aya Al-Shammari;MASUO Yusuke;FUJITA Ken-ichi;KUBOTA Yutaro;KATO Yukio, 日本薬物動態学会第34回年会, 11 Dec. 2019, つくば
  • ラベプラゾールの併用はカペシタビンと代謝物の体内動態に影響しない, 関戸　匡恵;藤田　健一;久保田　祐太郎;石川　文博;石田　博雄;柴沼　質子;佐々木　康綱, 第17回日本臨床腫瘍学会学術集会, 19 Jul. 2019, 京都
  • AUC of unbound form of regorafenib active metabolites M2 and M5 are associated with hand-foot syndrome, and ABCG2 polymorphism in Japanese patients with colorectal cancer, FUJITA Ken-ichi;KUBOTA Yutaro;MASUO Yusuke;ISHIDA Hiroo;KATO Yukio;SASAKI Yasutsuna, 120th American Society for Clinical Pharmacology and Therapeutics annual meeting, 14 Mar. 2019, Washington DC
  • Accumulation of active metabolite of anticancer agent regorafenib involves nonlinear hepatic distribution after repeated dose, AL-SHAMMARI Aya Hasan;MASUO Yusuke;FUJITA Ken-ichi;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, 2018 International Meeting on 22nd MDO and 33rd JSSX, 04 Oct. 2018, Kanazawa
  • Cytotoxic effects of tyrosine kinase inhibitors in keratinocytes and their possible relevance to ABC transporters, SHIMADA Kazuhiro;MASUO Yusuke;FUJITA Ken-ichi;SASAKI Yasutsuna;KATO Yukio, 2018 International Meeting on 22nd MDO and 33rd JSSX, 04 Oct. 2018, Kanazawa
  • Effects of severe renal failure on drug disposition and response, FUJITA Ken-ichi, 2018 International Meeting on 22nd MDO and 33rd JSSX, 02 Oct. 2018, Kanazawa
  • Mechanism of resistance to third-generation EGFR-TKI, rociletinib, in lung adenocarcinoma cells with EGFR-T790M mutation, YAMAOKA Toshimitsu;NAKATANI Kaori;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;IWAI Shinichi;OHMORI Tohru, 第77回日本癌学会学術総会, 28 Sep. 2018, 大阪
  • Assessment of paclitaxel-induced OATP1B inhibition in patients with non-small cell cancer by using endogenous substrates, FUJITA Ken-ichi;MORI Daiki;ISHIDA Hiroo;MIZUNO Tadahaya;MAEDA Kazuya;SASAKI Yasutsuna;KUSUHARA Hiroyuki, 第16回日本臨床腫瘍学会学術集会, 19 Jul. 2018, 神戸
  • Resistance mechanisms to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in lung adenocarcinoma cells harboring the EGFR-T790M mutation, NAKATANI Kaori;YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;FUJITA Ken-ichi;TAKI Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, 18th World Congress of Basic and Clinical Pharmacology (WCP2018), 05 Jul. 2018, Kyoto
  • Resistance mechanisms to third-generation EGFR TKIs in lung adenocarcinoma harboring EGFR T790M mutation, 中谷　香織;山岡　利光;大森　亨;大場　基;藤田　健一;滝　伊織;亀井　大輔;岩井　信市, 日本薬学会第138年会, 28 Mar. 2018, 金沢
  • 内在性基質をプローブとした抗がん剤パクリタキセルによるOATP1B阻害の検出, 森　大輝;石田　博雄;水野　忠快;藤田　健一;楠本　壮二郎;前田　和哉;佐々木　康綱;楠原　洋之, 第38回日本臨床薬理学会学術総会, 09 Dec. 2017, 横浜
  • 有機カチオントランスポーター1はチロシンキナーゼ阻害薬であるパゾパニブの肝取り込みに関与する, 藤田　健一;ELLAWATTY Waleed EA;増尾　友佑;石田　博雄;佐々木　康綱;加藤　将夫, 第38回日本臨床薬理学会学術総会, 08 Dec. 2017, 横浜
  • 薬剤師が関与する臨床試験（シンポジウム）, 藤田　健一, 第38回日本臨床薬理学会学術総会, 07 Dec. 2017, 横浜
  • Characterization of OATP1B1 inhibition by indole metabolites, SEBA Natsumi;MASUO Yusuke;FUJITA Ken-ichi;NAKAMICHI Noritaka;SASAKI Yasutsuna;KATO Yukio, 日本薬物動態学会第32回年会, 29 Nov. 2017, 東京
  • Involvement of ABC drug transporters in disposition of tyrosine kinase inhibitor regorafenib and its active metabolites after repeated oral dose, HASAN Aya;MASUO Yusuke;FUJITA Ken-ichi;YAMAZAKI Erina;KUBOTA Yutaro;NAKAMICHI Noritaka;SASAKI Yasutsuna;KATO Yukio, 日本薬物動態学会第32回年会, 29 Nov. 2017, 東京
  • Assessment of drug-drug interaction potency against OATP1B with paclitaxel using an endogenous substrate as an alternative probe, MORI Daiki;ISHIDA Hiroo;MIZUNO Tadahaya;FUJITA Ken-ichi;KUSUMOTO Sojiro;MAEDA Kazuya;SASAKI Yasutsuna;KUSUHARA Hiroyuki, 日本薬物動態学会第32回年会, 29 Nov. 2017, 東京
  • Keratinocyteにおける膜輸送体の発現とレゴラフェニブ分布に及ぼす影響, 島田　和弘;増尾　友佑;藤田　健一;山﨑　絵里名;久保田　祐太郎;中道　範隆;佐々木　康綱;加藤　将夫, 日本薬学会北陸支部第129回例会, 26 Nov. 2017, 金沢
  • Organic cation transporter 1 is involved in hepatic uptake of pazopanib in humans, FUJITA Ken-ichi;MASUO Yusuke;ISHIDA Hiroo;SASAKI Yasutsuna;KATO Yukio, 第76回日本癌学会学術総会, 30 Sep. 2017, 横浜
  • Involvement of ABC transporters in tissue distribution and disposition of active metabolites of regorafenib, FUJITA Ken-ichi;YAMAZAKI Erina;MASUO Yusuke;NAKAMICHI Noritaka;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, 第15回日本臨床腫瘍学会学術集会, 27 Jul. 2017, 神戸
  • Involvement of organic cation transporter 1 in hepatic uptake of pazopanib in humans, ISHIDA Hiroo;ELLAWATTY Waleed Elsayed Ahmed;FUJITA Ken-ichi;MASUO Yusuke;KATO Yukio;SASAKI Yasutsuna, 第15回日本臨床腫瘍学会学術集会, 27 Jul. 2017, 神戸
  • 日本における大腸がん術後補助化学療法のレジメン別医療経済評価, 髙田　昂輔;藤田　健一;滝　伊織;亀井　大輔;佐々木　康綱;岩井　信市, 日本薬学会第137年会, 25 Mar. 2017, 仙台
  • Unfit症例におけるがん薬物療法の至適化と臨床薬理学：腎障害がん患者におけるイリノテカンの特異な体内動態と投与法, 藤田　健一, 第37回日本臨床薬理学会学術総会, 02 Dec. 2016, 米子
  • レゴラフェニブと活性代謝物の体内動態解析とABC輸送担体の関与, 藤田　健一;増尾　友佑;山崎　絵里名;澁谷　俊紀;中道　範隆;佐々木　康綱;加藤　将夫, 第37回日本臨床薬理学会学術総会, 01 Dec. 2016, 米子
  • Involvement of ABC drug transporters in disposition of active metabolites of tyrosine kinase inhibitor regorafenib, YAMAZAKI Erina;MASUO Yusuke;FUJITA Ken-ichi;SHIBUTANI Toshiki;NAKAMICHI Noritaka;SASAKI Yasutsuna;KATO Yukio, 日本薬物動態学会第31回年会, 14 Oct. 2016, 松本
  • Inhibition of human hepatic transporter OATP1B1 by indole metabolites, 清波　夏実;増尾　友佑;藤田　健一;中道　範隆;佐々木　康綱;加藤　将夫, 日本薬物動態学会第31回年会, 14 Oct. 2016, 松本
  • Roles of BCRP and P-gp in disposition of regorafenib and active metabolites M-2 and M-5, FUJITA Ken-ichi;MASUO Yusuke;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, 第75回日本癌学会学術総会, 08 Oct. 2016, 横浜
  • 大腸がん術後補助化学療法レジメンの医療経済性の検討, 髙田　昂輔;藤田　健一;滝　伊織;亀井　大輔;佐々木　康綱;岩井　信市, 第26回日本医療薬学会年会, 18 Sep. 2016, 京都
  • Delayed elimination of SN-38 in cancer patients with severe renal failure: mechanism and appropriate irinotecan dose, FUJITA Ken-ichi, 第14回日本臨床腫瘍学会学術集会, 28 Jul. 2016, 神戸
  • 腎機能低下がん患者における特異なSN-38の体内動態とPBPKモデル, 藤田　健一, 医療薬学フォーラム2016/第24回クリニカルファーマシーシンポジウム, 25 Jun. 2016, 大津
  • 日本人の抗がん薬投与における認知機能評価法の確立に向けた検討, 髙田　昂輔;石井　麻菜;竹本　伊織;亀井　大輔;藤田　健一;佐々木　康綱;岩井　信市, 日本薬学会第136年会, 27 Mar. 2016, 横浜
  • 抗がん薬のリバーストランスレーショナルリサーチ：至適な薬物療法を目指して, 藤田　健一, 第18回　北海道大学薬学部　生涯教育特別講座　冬季講演会, 20 Feb. 2016, 札幌
  • 抗悪性腫瘍薬パゾパニブのUDP-グルクロン酸転移酵素(UGT)1A1に対する阻害効果, 岩瀬　万里子;藤田　健一;西村　有希;小口　勝司, 第36回日本臨床薬理学会学術総会, 10 Dec. 2015, 東京
  • 極めて腎機能の低下したがん患者におけるイリノテカン塩酸塩の至適投与量の推定, 藤田　健一;増尾　友祐;奥村　英典;佐々木　康綱;加藤　将夫, 第36回日本臨床薬理学会学術総会, 10 Dec. 2015, 東京
  • UFLC-MS/MS法によるヒト涙液中tegafur及び5-fluorouracilの高感度分析法, 小渕　律子;李　暁鵬;石田　博雄;熊澤　武志;廣澤　槙子;池田　賢一郎;藤城　雅也;藤田　健一;入戸野　晋;小林　一女;佐々木　康綱;高橋　春男;佐藤　啓造, 第62回昭和大学学士会総会, 28 Nov. 2015, 東京
  • 日本人を対象とした認知機能の評価法の検証, 髙田　昂輔;石井　麻菜;竹本　伊織;亀井　大輔;藤田　健一;佐々木　康綱;岩井　信市, 第62回昭和大学学士会総会, 28 Nov. 2015, 東京
  • Introduction -Innovation in Cancer Treatment-, FUJITA Ken-ichi, 日本薬物動態学会第30回年会, 14 Nov. 2015, 東京
  • Long-lasting inhibition of organic anion transporting polypeptide (OATP) 1B1 by endogenous uremic toxin indoxyl sulfate, KOGI Tatsuya;MASUO Yusuke;FUJITA Ken-ichi;KITAMURA Masanori;NAKAMICHI Noritaka;SASAKI Yasutsuna;KUNISHIMA Munetaka;KATO Yukio, 日本薬物動態学会第30回年会, 13 Nov. 2015, 東京
  • The estimation of drug interaction by pazopanib through the inhibition of UDP-glucuronosyltransferase (UGT) 1A1, IWASE Mariko;FUJITA Ken-ichi;NISHIMURA Yuki;OGUCHI Katsuji, 日本薬物動態学会第30回年会, 13 Nov. 2015, 東京
  • Comprehensive analysis of miRNA-variants in Japanese healthy subjects, non-small cell lung carcinoma and colorectal cancer patients, KATAYAMA Koki;GOTOH Saki;FUKAMI Tatsuya;ISHIDA Hiroo;KUBOTA Yutaro;KUSUMOTO Sojiro;FUJITA Ken-ichi;SASAKI Yasutsuna;NAKAJIMA Miki, 日本薬物動態学会第30回年会, 12 Nov. 2015, 東京
  • A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer, FUJITA Ken-ichi;YOSHINO Etsuko;KAWARA Kaori;MAEDA Kazuya;KUSUHARA Hiroyuki;SUGIYAMA Yuichi;YOKOYAMA Taro;KANETA Toshikado;ISHIDA Hiroo;SASAKI Yasutsuna, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
  • Personalized chemotherapy in breast cancer, 藤田　健一, 第9回日本緩和医療薬学会年会, 04 Oct. 2015, 横浜
  • A clinical pharmacokinetic microdosing study of docetaxel with Japanese cancer patients., FUJITA Ken-ichi;YOSHINO Etsuko;KAWARA Kaori;MAEDA Kazuya;KUSUHARA Hiroyuki;SUGIYAMA Yuichi;YOKOYAMA Taro;KANETA Toshikado;ISHIDA Hiroo;SASAKI Yasutsuna, The 40th European Society for Medical Oncology Annual Meeting (European Cancer Congress 2015), 27 Sep. 2015, Wien
  • Appropriate dose of irinotecan in cancer patients with severe renal failure (SRF), FUJITA Ken-ichi;MASUO Yusuke;OKUMURA Hidenori;SASAKI Yasutsuna;KATO Yukio, 第13回日本臨床腫瘍学会学術集会, 16 Jul. 2015, 札幌
  • Roles of efflux transporters in regorafenib pharmacokinetics, 澁谷　俊紀;増尾　友佑;藤田　健一;中道　範隆;佐々木　康綱;加藤　将夫, 日本薬学会第135年会, 26 Mar. 2015, 神戸
  • Optimization of the dose of irinotecan in cancer patients with severe renal failure (SRF) based on physiologically-based pharmacokinetic (PBPK) model., FUJITA Ken-ichi;MASUO Yusuke;OKUMURA Hidenori;SASAKI Yasutsuna;KATO Yukio, 116th American Society for Clinical Pharmacology and Therapeutics annual meeting, 05 Mar. 2015, New Orleans
  • Determination of tegafur and 5-fluorouracil in tear by HILIC-MS/MS., OBUCHI Ritsuko;LEE Xiao-Pen;HIROSAWA Makiko;ISHIDA Hiroo;FUJITA Ken-ichi;NITTONO Susumu;YOSHIDA Masato;SASAKI Yasutsuna;SATO Keizo;TAKAHASHI Haruo, Asia-ARVO (The Association for Research in Vision and Ophtalmology) 2015, 18 Feb. 2015, Yokohama
  • Increase in plasma unbound concentration and decrease in protein binding of SN-38 in cancer patients with severe renal failure, 藤田　健一;増尾　友祐;奥村　英典;砂川　優;嶋田　顕;河原　香織;秋山　祐子;佐々木　康綱;加藤　将夫, 第35回日本臨床薬理学会学術総会, 04 Dec. 2014, 松山
  • Inhibition of OATP1B1-mediated hepatic transport by uremic toxins, 小木　達也;増尾　友佑;藤田　健一;北村　正典;奥村　英典;中道　範隆;佐々木　康綱;国嶋　崇隆;加藤　将夫, 第36回生体膜と薬物の相互作用シンポジウム, 21 Nov. 2014, 徳島
  • Change in plasma protein binding of SN-38, an active metabolite of irinotecan, in cancer patients with severe renal failure (SRF), FUJITA Ken-ichi;OKUMURA Hidenori;MASUO Yusuke;SUNAKAWA Yu;SHIMADA Ken;KAWARA Kaori;AKIYAMA Yuko;SASAKI Yasutsuna;KATO Yukio, The 39th European Society for Medical Oncology annual meeting, 27 Sep. 2014, Madrid
  • Association of pharmacokinetics or pharmacogenomics with toxicity of erlotinib in patients with recurrent advanced non-small cell lung cancer., HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OKUDA Kentaro;OHNISHI Tsukasa;OHMORI Tohru;SASAKI Yasutsuna;TAMURA Atsuhisa;OHTA Ken, The 39th European Society for Medical Oncology annual meeting, 27 Sep. 2014, Madrid
  • Association of pharmacokinetics or pharmacogenomics with toxicity of erlotinib in patients with advanced NSCLC, HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;SHIRAI Takao;SUGIYAMA Tomohide;NAKASHIMA Masanao;OHMORI Tohru;SASAKI Yasutsuna;TAMURA Atsuhisa;OHTA Ken, 第12回日本臨床腫瘍学会学術集会, 19 Jul. 2014, 福岡
  • Pharmacokinetics of docetaxel in a clinical microdosing study with Japanese patients with cancer, 藤田　健一;吉野　悦子;河原　香織;前田　和哉;杉山　雄一;佐々木　康綱, 第12回日本臨床腫瘍学会学術集会, 17 Jul. 2014, 福岡
  • An internally and externally validated nomogram to predict severe neutropenia in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens., ICHIKAWA Wataru;UEHARA Keisuke;MINAMIMURA Keisuke;TANAKA Chihiro;TAKII Yasumasa;MIYAUCHI Hideaki;SADAHIRO Sotaro;FUJITA Ken-ichi;MORIWAKI Toshikazu;NAKAMURA Masato;TAKAHASHI Takehiro;TSUJI Akihito;SHINOZAKI Katsunori;MORITA Satoshi;ANDO Yuichi;OKUTANI Yukihiro;SUGIHARA Masahiro;SUGIYAMA Toru;OHASHI Yasuo;SAKATA Yuh, 50th American Society of Clinical Oncology annual meeting, 31 May 2014, Chicago
  • Pharmacokinetics, pharmacogenetics and toxicity of erlotinib in patients with non-small cell lung cancer, 廣瀬　敬;藤田　健一;楠本　壮二郎;白井　崇生;村田　泰則;大木　康成;杉山 　智英;石田　博雄;中嶌　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;佐々木　康綱;田村　厚久;大田　健, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
  • TNF transactivation of EGFR protects EGFR-TKI, gefitinib induced pulmonary epithelial cell apoptosis and injury in TNF transgenic mice., YAMAOKA Toshimitsu;OKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;TOYA Etsuko;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori;SASAKI Yasutsuna, 105th American Association for Cancer Research annual meeting, 07 Apr. 2014, San Diego
  • Basic and clinical studies to establish optimal dosing of irinotecan in cancer patients with severe renal failure who were undergoing dialysis., 藤田　健一, 第47回制癌剤適応研究会, 07 Mar. 2014, 名古屋

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.